DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences

Author： Thomas Xavier  

Publisher： Informa Healthcare

ISSN： 1746-0441

Source： Expert Opinion on Drug Discovery, Vol.7, Iss.11, 2012-11, pp. : 1039-1051

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: Achievements and challenges

By Lübbert Michael   Kuendgen Andrea  

Cancer, Vol. 121, Iss. 4, 2015-02 ,pp. : 498-501

Blackwell Publishing

Access to resources Recommend Favorite

New therapeutic approaches to acute myeloid leukemia

By Uchida Hideo   Inokuchi Koiti   Watanabe Reiko   Tokuhira Michihide   Kizaki Masahiro  

Expert Opinion on Drug Discovery, Vol. 3, Iss. 6, 2008-06 ,pp. : 689-706

Informa Healthcare

Access to resources Recommend Favorite

The clinical development of FLT3 inhibitors in acute myeloid leukemia

By Knapper Steven  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 10, 2011-10 ,pp. : 1377-1395

Informa Healthcare

Access to resources Recommend Favorite

Novel and Emerging Drugs for Acute Myeloid Leukemia: Pharmacology and Therapeutic Activity

By  

Current Medicinal Chemistry, Vol. 18, Iss. 5, 2011-02 ,pp. : 638-666

Bentham Science Publishers

Access to resources Recommend Favorite

Signal transduction in Acute Myeloid Leukemia – Implications for Novel Therapeutic Concepts.

By  

Current Cancer Drug Targets, Vol. 15, Iss. 9, 2015-11 ,pp. : 803-821

Bentham Science Publishers

Access to resources Recommend Favorite